Shanghai-based Mabwell has been listed on the main board of the Hong Kong Stock Exchange and entered the market with the stock code 02493.HK.
Founded in 2017, Mabwell is an innovative biopharmaceutical company with a full industrial chain layout. Focusing on dealing with tumors and age-related diseases, the company covers multiple treatment fields, with 15 key varieties now in preclinical, clinical, or marketing stages.
The funds raised this time round will mainly be used for clinical trials of its core product 9MW2821 targeting multiple indications at different stages, research and development of other pipeline varieties for tumors and age-related diseases with huge clinical demand, and product commercialization.
The company's antibody and recombinant protein drug industrialization base, which complies with standards in China, US, and the EU, has been put into use in China Medical City, Taizhou, Jiangsu province.
Its large-scale commercial production bases in Jinshan, Shanghai and China Medical City are all now under construction.